BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices. The order total encompasses commitments to governments all over the globe, including the U.S., […]
Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system […]
Carbon Health acquires Steady Health and its diabetes platform
Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create […]
Dexcom touts CGM studies, shares data on next-gen G7
Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the Mobile study, published in JAMA, observed 175 ethnically and socioeconomically diverse adults (30 years old […]
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study […]
Medtronic touts real-world results for MiniMed 780G insulin pump
Medtronic (NYSE:MDT) today announced positive real-world outcomes for thousands of patients using the MiniMed 780G insulin pump system. Fridley, Minn.-based Medtronic’s MiniMed 780G system automates and personalized the delivery of basal insulin through adjustments every five minutes for 24 hours a day. It includes an advanced algorithm designed to automatically correct highs every five minutes […]
GM Instruments, Sensonics partner on nasal and oral measurement devices
GM Instruments announced today that it partnered with Sensonics to develop devices for the quantitative assessment of nasal and oral function. The companies tout the first-of-its-kind partnership as a bringing together of sensory and engineering expertise for evaluating and treating nasal and oral diseases. Additionally, the companies expect the partnership to establish the influences of […]
FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health
Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere. Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis. Xipere works with Clearside’s proprietary SCS Microinjector to access the back of […]
Lyra inks $135M partnership to expand chronic rhinosinusitis treatment in Asia
Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement […]
Noveome Biotherapeutics inks licensing deal for SipNose drug delivery device
Noveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose’s proprietary drug delivery device. Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, was licensed to Noveome to deliver the Pittsburgh-based company’s ST266 biologic to the central nervous systems, according to a news release. CT6 allows aerosolized […]
